Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
loading.........
 

Sydney, Mar 22, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (googlechartASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

To view the video interview, please visit:
http://www.abnnewswire.net/press/en/96630/anr

To view the Pitt Street Research Report - "Following the Gut" , please visit:
http://abnnewswire.net/lnk/33S39548

About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

Anatara Lifesciences Ltd
E: info@anataralifesciences.com
WWW: www.anataralifesciences.com



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 27) (Last 30 Days: 76) (Since Published: 26828)